Neuro3d Identifies Candidate Compound and Extends Collaboration
"The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities. As this achievement is outside the psychiatric arena which is our main area of focus, we are now demonstrating the ability to leverage our expertise into other indications," noted Charles Woler, CEO of Neuro3d. "We look forward to the continued success of our collaboration with J&JPRD."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.